Skip to main content
. Author manuscript; available in PMC: 2018 Feb 15.
Published in final edited form as: Biochem Pharmacol. 2016 Dec 8;126:51–68. doi: 10.1016/j.bcp.2016.12.003

Fig. 10.

Fig. 10

Fig. 10

Western blot analysis showing pachycladin A treatment effects on MDA-MB-231 breast cancer signaling after 48 h treatment in human MDA-MB-231 cancer cells. (A) Treatment with 1 caused a dose-dependent inhibition of EGFR phosphorylation without any effect on its total levels, compared to vehicle-treated control group. (B-E) Treatment with 1 caused a dose-dependent phosphorylation inhibition of EGFR downstream signaling proteins, including Akt, MAPK, FAK, and Brk, without any effect on their total levels, compared to vehicle-treated control group. (F) No significant inhibition was observed on c-Met signaling. Scanning densitometric analysis was performed on all blots done in triplicate and the integrated optical density of each band was normalized with corresponding β-tubulin, as shown in bar graphs below their respective Western blot images. Vertical bars in the graph indicate the normalized integrated optical density of bands visualized in each lane ± S.D., *P <0.05 as compared with vehicle-treated controls.